Next Phase Newsletter

A joint venture investment company backed by two large corporations is investing in healthcare from a $100 million fund. The firm strives to catalyze the success of digital medicine products, services and business models by investing in early-stage companies. The firm prefers to co-invest and makes equity investments of up to $5 million per deal. The firm is currently seeking opportunities in the US, EU, and Israel.

The firm is seeking entrepreneurs using digital technology to transform pharmaceutical products, sales and marketing, R&D, and enterprise operations. The firm also considers personalized medicine using -omics science. Examples may include enterprise software solutions that improves clinical care or mobile sensors for disease management in home care settings. The firm is less interested in consumer products. The firm is seeking products with some market traction or credible customers.

The firm works with strong founders who demonstrate full understanding of their market sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A fund backed entirely by a consortium of Senior Living Systems looks to allocate anywhere from $.5 – $5 million into commercial stage companies with products or services for the aging and elderly population, typically in a series A, B or C round. The firm has the majority of its portfolio dedicated to companies based in the US although they do have the ability to invest internationally as well. The firm could make as many as 4-5 investments over the next 6-12 months.

The firm is looking for companies operating in the Healthcare IT and Services sectors, with products or services for the aging and elderly population. The firm is only interested in investing in companies with products already on the market that have been able to demonstrate some market traction prior to investment.

The firm is looking for privately held companies with experienced management teams. The firm prefers there to be a complete management team in place prior to investment and often looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A transatlantic healthcare technology focused on seed-stage funding sources opportunities from global institutions, leading technology incubators and its deep healthcare network. The firm typically leads investments as the first money into projects spun out of these entities. The firm focuses on companies based in the U.S. and the UK.

In the Life Sciences space, the firm is currently seeking new investments in therapeutics, diagnostics, and digital health targeting chronic disease. In terms of stage of development, The firm focuses on early stage technology, which has demonstrated proof of concept and received grant funding.

In the early stages of the company’s development, the firm provides extensive management support including technical guidance, administrative support, legal, IP and commercial expertise. As companies mature through key milestones, the firm will recruit experienced industry leading CEOs to drive the next phase of growth, attract additional external capital and secure favourable exits. The firm seeks to invest in game-changing technologies based on strong science with great commercial potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Sydney, Australia makes early-late stage investments into several industries with a focus on transformative technologies, including: Life Sciences, IT, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics, and food security. The firm has raised 2 funds to date and currently has A$ 200M in funds under management, and is investing with a primary focus on companies raising Series B rounds onwards, though will consider companies raising Series A. Depending on the stage, the firm can invest from A$ 4M up to A$ 20M per company. Most of the firm’s investments are in Australian-based companies but 20% of investments are for off-shore investments outside of Australia, as the firm has looked at technology in the USA, Israel, and Singapore. The firm is actively seeking 3-4 new investment opportunities within the next year.

In the Life Sciences, the firm seeks to invest in biotech, specialty pharma, medical technology/device, diagnostics, and healthcare IT. The firm looks at post-Ph I clinical-stage products that have a strong proof-of-concept at a minimum, and typically invests in products with well-progressed and well-defined regulatory and reimbursement pathways. If a medical device, the product should be approaching profitability with capital required to fuel growth and global expansion. The firm is only interested in indications with a significant global market, and will not look at biosimilars, generics, and indications and technology that require large rounds in their Ph III-study.

In Healthcare IT, the firm is interested in eHealth apps, self-management and CRM software technology. The firm is also interested in food and environmental biotech opportunities.

The firm requires board representation post-investments. The firm will actively help with hiring a full management team, senior management team, and board, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Europe-based pharma firm is interested in partnerships with with early-stage biotech companies, usually structured in the form of rights, co-marketing, or R&D collaborations. The firm is open to partnering with companies globally.

The firm focuses on 5 disease areas; cardiovascular disease (heart failure, ischemia, atrial fibrillation), metabolism (type 2 diabetes and complications of diabetes), oncology (apoptosis, immunotherapy, proliferation & differentiation pathways, protein degradation, and epigenetics), CNS (cognitive impairment, neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, multiple sclerosis, and ALS), and rheumatology (osteoarthritis, inflammatory and immune diseases, and muscle pathologies). Within these disease areas, the firm focuses on unmet medical needs and will consider partnering on any molecule type (small molecule, biologic or cell therapy), but is only interested in novel therapeutic products; the firm does not invest in drug delivery or biosimilars. The firm will consider opportunities from target stage to late clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in California has raised its first fund in 2016.  The fund’s investment strategy is somewhat flexible, but seeks to initially invest in series A rounds in the range of $2M-$3M then provide capital throughout the company’s life via additional investments. The firm may write smaller checks (in the range of $250K) to companies that are of very high interest to the fund, but are deemed as too early, to serve as a placeholder for subsequent financing rounds. In terms of capital structure, the firm prefers to participate in priced equity rounds, however convertible notes or other structures may be considered in certain cases. The firm will act as a lead or follow-on investor depending on the nature/terms of the deal and other investors participating in the round.

The firm is most interested in disruptive technologies that target extreme inefficiencies in the healthcare system, such as digital health solutions based on artificial intelligence or big data platforms, as well as cutting-edge technologies and applications in the field of synthetic biology, or other technologies taking elements of data science to improve molecular processes. The firm is not interested in traditional medical devices and diagnostics, but rather devices whose core IP lies within in the backend or software component of the technology.

The firm is open to companies globally, but prefers to invest in companies based on the West Coast. Typically, companies that aren’t located in the U.S. would need to have some operations based in the United States. A lot of emphasis is placed on the strength of the management team when making an investment decision, and the firm seeks to work with entrepreneurs who have a strong understanding of their market and sound logic behind why their vision and business model will be successful. Although successful, repeat entrepreneurs are highly valued, the firm will work with entrepreneurs of all experience levels. Board seats are not required along with an investment, but may be sought depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage venture capital firm founded in 2008 and based in San Francisco, CA has recently closed a $125M fund, and will invest in series A rounds with initial investments in the range of $2M-$5M, with access to additional capital for follow-on investments if needed. The firm prefers priced equity rounds, and acts nearly exclusively as a lead investor.

The firm is traditionally a tech-oriented VC, however the firm is open to evaluating companies in the health IT space, whether they are developing consumer facing products or enterprise solutions for health systems with the caveat being that the core business can scale with capital efficiency. The firm is looking for capital efficient technology solutions, with the number one disqualifier of potential portfolio companies being capital intensity.

The firm is most interested in U.S. companies, and will consider companies located globally only if they are based near a trusted colleague/investor that can interact with the company. While the firm values experienced entrepreneurs with an exit on their résumé, the firm is open to working with entrepreneurs of all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com